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Abstract
Objective:  Therapeutic  hypothermia  reduces  cerebral  injury  and  improves  the  neurological
outcome  secondary  to  hypoxic  ischemic  encephalopathy  in  newborns.  It  has  been  indicated
for asphyxiated  full-term  or  near-term  newborn  infants  with  clinical  signs  of  hypoxic-ischemic
encephalopathy  (HIE).
Sources:  A  search  was  performed  for  articles  on  therapeutic  hypothermia  in  newborns  with
perinatal asphyxia  in  PubMed;  the  authors  chose  those  considered  most  signiﬁcant.
Summary  of  the  ﬁndings:  There  are  two  therapeutic  hypothermia  methods:  selective  head
cooling and  total  body  cooling.  The  target  body  temperature  is  34.5 ◦C  for  selective  head  cool-
ing and  33.5 ◦C  for  total  body  cooling.  Temperatures  lower  than  32 ◦C  are  less  neuroprotective,
and temperatures  below  30 ◦C  are  very  dangerous,  with  severe  complications.  Therapeutic
hypothermia  must  start  within  the  ﬁrst  6  h  after  birth,  as  studies  have  shown  that  this  rep-
resents the  therapeutic  window  for  the  hypoxic-ischemic  event.  Therapy  must  be  maintained
for 72  h,  with  very  strict  control  of  the  newborn’s  body  temperature.  It  has  been  shown  that
therapeutic  hypothermia  is  effective  in  reducing  neurologic  impairment,  especially  in  full-term
or near-term  newborns  with  moderate  hypoxic-ischemic  encephalopathy.
Conclusion:  Therapeutic  hypothermia  is  a  neuroprotective  technique  indicated  for  newborn
infants with  perinatal  asphyxia  and  hypoxic-ischemic  encephalopathy.
© 2015  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  All  rights  reserved. Please cite this article as: Silveira RC, Procianoy RS. Hypothermia therapy for newborns with hypoxic ischemic encephalopathy. J Pediatr
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Hipotermia  terapêutica  para  recém-nascidos  com  encefalopatia  hipóxico  isquêmica
Resumo
Objetivo:  A  hipotermia  terapêutica  reduz  a  lesão  cerebral  e  melhora  o  desfecho  neurológico
de recém-nascidos  após  insulto  hipóxico  isquemico.  Indicada  para  recém-nascidos  a  termo  ou
próximo do  termo  com  evidência  de  asﬁxia  perinatal  e  Encefalopatia  Hipóxico  Isquemica  (EHI).
Fontes dos  dados:  Foi  feita  uma  procura  no  PubMed  por  publicac¸ões  sobre  hipotermia  terapêu-
tica em  recém-nascidos  com  asﬁxia  perinatal  e  selecionadas  aquelas  julgadas  mais  relevantes
pelos autores.
Síntese  dos  dados: Há  duas  técnicas  de  resfriamento  corpórea:  hipotermia  seletiva  da  cabec¸a
e hipotermia  corpórea  total.  A  temperatura  de  resfriamento  deve  ser  34,5 ◦C  para  seletiva  de
cabec¸a e  33,5 ◦C  para  corpórea  total;  temperaturas  inferiores  a  32 ◦C  são  menos  neuroprote-
toras e  abaixo  de  30 ◦C  há  efeitos  adversos  sistêmicos  graves.  Indica-se  o  início  da  hipotermia
terapêutica  até  6  horas  após  o  nascimento,  pois  estudos  evidenciaram  que  esta  é  a  janela  ter-
apêutica  da  agressão  hipóxico  e  isquêmica.  A  hipotermia  deve  ser  mantida  por  72  horas  com
rigorosa monitorizac¸ão  da  temperatura  corporal  do  recém-nascido.  A  hipotermia  tem  sido  efe-
tiva em  reduzir  seqüelas  neurológicas,  principalmente  em  recém-nascidos  de  termo  ou  próximo
do termo  com  encefalopatia  hipóxico  isquêmica  moderada  e  em  melhorar  o  prognóstico  em
longo prazo  dos  recém-nascidos  com  EHI.
Conclusão:  A  hipotermia  terapêutica  é  uma  técnica  neuroprotetora  indicada  para  recém-
nascidos com  asﬁxia  perinatal.
©  2015  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  Todos  os  direitos
reservados.
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dIntroduction
More  than  a  decade  ago,  experimental  evidence,  and  sub-
sequently,  good-quality  clinical  trials  initially  appeared,
suggesting  that  therapeutic  hypothermia  reduces  brain  dam-
age  and  improves  neurological  outcome  after  neonatal
hypoxic-ischemic  injury.1--4 The  best  result  in  terms  of
therapeutic  hypothermia  prognosis  seems  to  be  in  mild
to  moderate  injuries,  while  the  real  beneﬁt  has  been
questioned  for  infants  with  severe  encephalopathy.  A  mul-
ticenter  study  by  the  NICHD  (National  Institute  of  Child
Health  and  Human  Development)  showed  that  cases  persist-
ing  with  severe  hypoxic-ischemic  encephalopathy  (HIE)  signs
and  altered  neurological  assessment  at  the  discharge  from
the  neonatology  service  after  72  h  of  therapeutic  hypother-
mia  had  higher  mortality  or  morbidity  in  the  follow-up  at  18
months  of  life.5
The  extent  of  cerebral  injury  following  a  hypoxic-
ischemic  insult  basically  depends  on  the  balance  between
the  causative  mechanisms  of  irreversible  injury,  such  neu-
ronal  necrosis  or  persistent  inﬂammation,  and  endogenous
protection  (acute  phase  response,  recovery,  and  neu-
ronal  repair).  The  neuroprotective  strategy  of  therapeutic
hypothermia  involves  the  modulation  of  some  irreversible
injury  mechanisms,  such  as  inﬂammatory  cascade  inhibition,
reduced  production  of  reactive  oxygen  species,  reduction  in
the  metabolic  rate  with  reduced  oxygen  consumption  and
carbon  dioxide  production,  and  an  endogenous  neuropro-
tective  effect.6--9The  objective  of  this  review  is  to  understand  the  mech-
anism  of  action  of  therapeutic  hypothermia,  searching  for
evidence  in  the  literature  to  establish  the  type  of  newborn
that  is  a  good  candidate  for  this  type  of  therapy,  describing
r
e
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ghe  protocol,  possible  complications,  and  supportive  care
or  the  management  of  newborns  submitted  to  therapeutic
ypothermia.
echanism of action of therapeutic
ypothermia
ypothermia  results  in  a  reduction  of  cerebral  metabolism
y  approximately  5%  for  each  1 ◦C  decrease  in  body  temper-
ture,  which  delays  the  onset  of  anoxic  cell  depolarization.
he  reduction  in  excitatory  amino  acids  such  as  aspartate
nd  glutamate,  during  the  ischemic  phase  of  therapeutic
ypothermia,  is  due  to  the  fact  that  they  promote  depo-
arization  delay  and  intracellular  calcium  inﬂux  reduction.
hese  effects  have  been  demonstrated  in  different  man-
ers  in  experimental  models  of  ischemia  and  reperfusion  in
odents  after  cardiac  arrest  in  young  adult  dogs,  or  during
nd  immediately  after  hypoxic-ischemic  injury  in  newborn
igs.8
Hypoxia-ischemia-reperfusion  injury  in  the  central  ner-
ous  system  activates  a  pro-inﬂammatory  cascade  of  events
haracterized  by  leukocyte  inﬂux,  including  polymorphonu-
lear  cells  and  monocytes,  and  microglial  activation.  Many
f  these  inﬂammatory  reactions  are  mediated  by  cytokines,
specially  neuronal  apoptosis  modulation.  The  cytokines
ith  best-known  actions  in  the  CNS  are:  TNF-, IL-1, and
L-6.  Part  of  the  neuroprotective  effect  of  hypothermia  is
ue  to  proinﬂammatory  pathway  blockade.6,8
Cytokines  are  mediators  of  the  systemic  inﬂammatory
esponse  activation  mechanism.  In  a  situation  of  ischemia,
nhanced  endothelial  activation  occurs  by  monocyte  acti-
ation,  stimulating  production  of  TNF-, which  promotes
reater  endothelial  activation.  The  production  of  IL-6,
S Silveira  RC,  Procianoy  RS
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Meet both criteria:
1. Evidence of perinatal asphyxiaumbilical cord blood
Umbilical cord blood gas analysis or in the first hour of
life with pH < 7.0 or EB < -16
Or history of perinatal acute event (placental abruption,
cord prolapse)
Or Apgar score ≤5 in the 10th minute of life
Or need for ventilation beyond the tenth minute of life
                                          and
2. Evidence of moderate to severe encephalopathy before 6 hours of life:
Seizures, level of consciousness, spontaneous activity, posture, tone,
reflexes, and autonomic system.
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L-1, IL-8,  and  PAF  (platelet  activating  factor)  occurs
hrough  several  interactions.10 Furthermore,  through  the
ctions  of  soluble  receptors,  IL-6,  IL-1, and  TNF- increase
he  expression  of  adhesion  molecules,  especially  intercellu-
ar  adhesion  molecule-1  (ICAM-1)  in  endothelial  cells  and  in
strocytes,  facilitating  leukocyte  inﬁltration  and  increasing
eukocyte  activation,  with  consequent  promotion  of  sys-
emic  inﬂammatory  response  as  the  ﬁnal  result.  Cytokines
nduce  nitric  oxide  synthetase  enzyme,  which,  together  with
NF-  and  IL-1, promotes  neurotoxic  effects.8,9 Caspase
ctivation  may  induce  local  inﬂammatory  response  involving
nergy  consumption  and  increase  in  the  number  of  apop-
otic  neurons,  with  the  possibility  of  injury  reversal,  which
s  neuroprotective.6
In  experimental  models,  prolonged  hypothermia  mecha-
ism  (72  h)  induced  the  reduction  of  necrosis  and  neuronal
poptosis.7,11 Cytochrome  C  suppression  by  mitochondria
as  demonstrated,  as  well  as  activation  of  caspase  3  in  the
ortex,  thalamus,  and  hippocampus  of  rats  with  HIE  that
eceived  hypothermia  therapy  for  72  h.11
herapeutic window
ypoxic-ischemic  insult  involves  an  ongoing  injury  process,
here  the  severity  of  HIE  depends  on  the  duration  and
xtent  of  this  process.  The  central  role  of  therapeutic
ypothermia  in  neuroprotection  involves  the  interruption  or
eduction  of  this  process;  essentially  divided  into  acute  or
rimary  phase,  in  which  some  neural  cells  die  and  others
ecover,  at  least  partially;  the  latent  phase,  with  partially
ecovered  oxidative  metabolism,  even  with  suppressed  elec-
roencephalographic  activity9;  and  the  secondary  phase,
hich  occurs  after  moderate  to  severe  injury,  initiating
ours  later,  on  average  within  6  up  to  15  h,  clinically
anifested  by  the  presence  of  seizures,  cytotoxic  edema,
ccumulation  of  excitatory  amino  acids,  and  failure  of
itochondrial  oxidative  activity,  which  is  the  main  factor
ssociated  with  neuronal  death.
It  is  important  to  act  before  the  secondary  phase,  dur-
ng  the  therapeutic  window  of  opportunity  when  apoptotic
eurons  are  able  to  recover.  The  degree  of  energy  failure
etermines  the  type  of  neuronal  damage  (death)  during  the
arly  and  late  stages,  and  the  degree  of  trophic  support
nﬂuences  angiogenesis  and  neurogenesis  during  the  recov-
ry  phase  of  HIE.
Although  exactly  when  the  brain  injury  becomes
rreversible  has  yet  to  be  precisely  established,  there  are
onsistent  data  indicating  that  the  latency  phase,  also
nown  as  the  early  phase  of  recovery  from  transient  restora-
ion  of  cerebral  oxidative  metabolism,  before  the  start  of
he  secondary  phase  of  energy  failure,  represents  the  best
indow  for  therapeutic  intervention.8 Because  this  is  an
ngoing  process,  these  phases  are  close,  and  therefore  the
ransition  to  the  moment  of  irreversible  cell  death  is  almost
mperceptible.11,12
Since  the  ﬁrst  series  of  clinical  cases  of  perinatal
sphyxia,  therapeutic  hypothermia  initiation  has  been  indi-
ated  within  6  h  after  birth,  due  to  all  the  experimental
vidence  demonstrating  that  this  represents  the  therapeutic
indow  to  inhibit  or  reduce  the  hypoxic-ischemic  injury.11
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oFigure  1  Therapeutic  hypothermia  indication.
election of newborn candidates for
herapeutic hypothermia
n  the  2010  Consensus,  the  International  Consensus  on  Car-
iopulmonary  Resuscitation  (ILCOR)  included  the  indication
f  therapeutic  hypothermia  for  every  newborn  at  term  or
ear  term  who  had  developed  moderate  to  severe  HIE,  using
 speciﬁc  protocol  and  follow-up  coordinated  by  the  regional
eference  care  system.13
Overall,  the  indication  of  therapeutic  hypothermia  for
ewborns  follows  the  recommendations  found  on  the  site  of
he  Brazilian  Society  of  Pediatrics  and  ILCOR13,14:  newborns
ith  gestational  age  >  35  weeks,  birth  weight  >  1800  g,  who
ave  fewer  than  6  h  of  life,  and  meet  the  following  criteria.14
Evidence  of  perinatal  asphyxia:  umbilical  cord  blood  gas
nalysis  or  in  the  ﬁrst  hour  of  life  with  pH  <7.0  or  base
xcess  (EB)  <−16  or  history  of  perinatal  acute  event  (pla-
ental  abruption,  cord  prolapse),  or  Apgar  score  of  5  or  less
n  the  10th  minute  of  life,  or  need  for  mechanical  ventila-
ion  beyond  the  10th  minute  of  life,  or  any  of  the  following
ssociated  with  evidence  of  moderate  to  severe  encepha-
opathy  before  6  h  of  life:  seizure,  level  of  consciousness,
pontaneous  activity,  posture,  tone,  reﬂexes,  and  autonomic
ystem  (Fig.  1).14
A  Cochrane  review  reinforced  the  beneﬁt  of  therapeu-
ic  hypothermia  in  full-term  or  late-preterm  newborns  with
IE,  according  to  the  above  mentioned  protocol.  A  total
f  11  randomized  controlled  trials  and  1505  infants  with
oderate  to  severe  encephalopathy  and  evidence  of  intra-
artum  asphyxia  were  included  in  this  review.  Therapeutic
ypothermia  resulted  in  a  statistically  signiﬁcant  and  clini-
ally  important  reduction  in  the  combined  outcome  of  death
r  severe  neurodevelopmental  delay  at  18  months  of  age.15
Patterns  of  brain  injury  on  the  magnetic  resonance  imag-
ng  (MRI)  with  different  clinical  presentations  after  the
nsult,  and  neurological  outcome  directly  associated  with
euroimaging  ﬁndings  and  less  with  the  immediate  clinical
ndings,  were  observed  in  neonates  with  HIE.16 The  need
or  sedation  and  analgesia  in  a  newborn  in  the  ﬁrst  hours
fter  birth  is  one  explanation  for  the  difﬁculty  in  the  clin-
cal  evaluation  after  HIE  and  decision  to  treat.17 In  these
ituations,  video-electroencephalogram  (video-EEG)  moni-
oring  in  every  newborn  with  HIE,  which  is  the  gold  standard
or  assessment  of  electrographic  seizure,  could  be  useful
n  the  screening  of  newborn  candidates  for  therapeutic
ypothermia.  The  presence  of  electrographic  seizures  with-
ut  clinical  manifestation  was  determined  by  video  EEG  in
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fHypothermia  for  neonates  
approximately  half  of  the  newborns  with  HIE  submitted  to
therapeutic  hypothermia.17--19
Amplitude-integrated  electroencephalogram  (aEEG)  has
been  used  in  a  few  studies  to  decide  whether  a  new-
born  with  encephalopathy  is  a  candidate  for  therapeutic
hypothermia.20,21 In  neonates  with  mild  HIE,  a  study  with
a  small  sample  size  showed  to  be  more  effective  in  iden-
tifying  which  patients  with  encephalopathy  would  develop
severe  neurological  diseases.22
The  use  of  aEEG  is  relevant  considering  that  the  time
to  decide  whether  a  newborn  is  a  candidate  for  therapeutic
hypothermia  is  limited,  and  any  mistakes  regarding  the  start
of  such  a  promising  treatment  should  be  avoided;  neverthe-
less,  the  aEEG  is  not  routinely  used  to  select  candidates  for
this  type  of  therapy.13--15,23
Results and  prognosis after therapeutic
hypothermia
Hypothermia  has  been  effective  in  reducing  neurological
sequelae,  particularly  in  newborns  with  moderate  HIE,  and
in  improving  the  long-term  prognosis  of  newborns  with  HIE.
Meta-analysis  studies  have  shown  that  the  use  of  therapeu-
tic  hypothermia  decreases  mortality  and  improves  prognosis
regarding  the  neurodevelopment  of  infants  with  HIE.1,4,5
There  is  evidence  from  three  large  randomized  trials
and  two  small  clinical  trials  demonstrating  that  induced
hypothermia  (33.5--34.5 ◦C),  when  started  within  the  6-h
window  after  the  birth  of  full-term  asphyxiated  newborns,
is  beneﬁcial  in  reducing  mortality  and  neurodevelopmental
delay  assessed  by  the  Bayley  scale  in  the  follow-up  at  18
months  of  life.20,21,24--26 The  results  are  better  if  there  are
well-organized  protocols  for  hypothermia  indication  and
induction,  as  well  as  adequate  rewarming.1,24
In  the  context  of  the  newborn  candidate  for  thera-
peutic  hypothermia,  it  has  been  observed  that  maternal
hyperthermia  is  associated  with  high  incidence  of  perina-
tal  respiratory  depression,  neonatal  seizures,  cerebral  palsy,
and  higher  neonatal  mortality,  conﬁrming  the  deleterious
effect  of  hyperthermia.  It  is  possible  that  in  situations  of
maternal  chorioamnionitis  and  fetal  inﬂammatory  response
syndrome  in  utero, the  result  of  therapeutic  hypother-
mia  is  limited.  In  the  presence  of  infection/inﬂammation
in  a  randomized  clinical  trial  of  therapeutic  hypothermia
after  encephalopathy  secondary  to  bacterial  meningitis,  the
choice  of  therapeutic  hypothermia  was  ineffective.27 MRI
data  obtained  after  therapeutic  hypothermia  in  a  small
prospective  study  of  newborns  whose  mothers  had  histolog-
ical  chorioamnionitis  demonstrated  that  hypothermia  was
less  effective  in  this  infectious  condition.28
Hyperthermia  after  neonatal  HIE  is  associated  with
higher  mortality  and  adverse  neurological  outcome  at  18--22
months  of  age  and  at  6--7  years  of  age,  with  lower  intel-
ligence  scores  and  an  up  to  3.5-fold  higher  incidence  of
moderate  to  severe  cerebral  palsy  in  newborn  infants  with
higher  temperatures  in  the  ﬁrst  days  after  birth.29,30 There-
fore,  high  temperature  after  the  hypoxic  ischemic  insult
represents  an  additional  risk  factor  for  adverse  outcomes
and,  avoiding  hyperthermia  is  as  important  as  therapeutic
hypothermia  in  these  cases.
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The  results  of  therapeutic  hypothermia  are  strongly  inﬂu-
nced  by  the  severity  of  HIE.  Several  experimental  and
linical  studies  have  concluded  that  the  neuroprotective
ction  of  therapeutic  hypothermia  is  less  effective  in  severe
IE,  partly  because  the  latency  period  is  even  shorter,  with
igher  energy  failure  and  accelerated  neuronal  necrosis  of
ortical  gray  matter,  basal  ganglia,  thalamus,  and  serious
amage  to  the  white  matter,  associated  with  cerebral  palsy
t  varying  levels.1 A  meta-analysis  showed  that  therapeutic
ypothermia  was  signiﬁcantly  protective  for  the  outcome
eath  and  disability  in  cases  of  HIE,  with  better  results  in
oderate  than  in  severe  cases.  The  challenge  is  to  able  to
ndividualize  the  decision  to  initiate  therapeutic  hypother-
ia  in  severe  cases,  especially  since  the  establishment  of
ncephalopathy  severity  is  difﬁcult,  imprecise,  and  subjec-
ive  when  based  only  on  clinical  evaluation.4
All  patients  undergoing  hypothermia  therapy  should
e  followed  longitudinally  to  establish  the  long-term
utcome.5,13 Moreover,  for  the  hypothermia  to  be  effec-
ive,  a  high  level  of  neonatal  intensive  care  support  is
equired;  not  all  centers  are  capable  of  performing  ther-
peutic  hypothermia.
rotocol: establishing safety and efﬁcacy
andomized  clinical  trials  have  employed  two  body  cool-
ng  techniques  in  order  to  inhibit,  reduce,  and  improve
rain  lesion  evolution  and  neurological  sequelae  resulting
rom  HIE:  selective  head  hypothermia20 with  temperatures
educed  to  34.5 ◦C,  and  total  body  hypothermia  with  tem-
erature  reduced  to  33.5 ◦C4,24; both  techniques  recommend
he  maintenance  of  hypothermia  for  72  h.  According  to
LCOR,  both  techniques  are  appropriate,  and  the  rewarming
hase  must  be  slow  and  gradual,  conducted  over  a  4-h  period
ith  an  increase  of  0.5 ◦C  per  hour  until  the  temperature
eaches  36.5 ◦C;  this  process  aims  to  prevent  complications
aused  by  rapid  rewarming.1,13,15
Selective  head  cooling  is  performed  with  a  helmet,  and
otal  body  cooling  with  a  thermal  mattress  in  which  the
nfant  is  placed,  with  a  servo  control  apparatus  to  regu-
ate  the  mattress  temperature  higher  or  lower  according  to
he  patient’s  temperature.21,24 The  use  of  ice  packs  is  not
he  best  method  because  the  monitoring  of  thermal  control
s  precarious,  although  a  randomized  study  employed  this
echnique  in  moderate  HIE,  recommending  it  as  an  alter-
ative  if  started  within  6  h  after  the  event  and  until  the
ewborn  is  able  to  be  transferred  to  a  referral  center  to
ndergo  therapeutic  hypothermia.31
The  temperature  must  remain  above  33 ◦C  during  the
ntire  hypothermia  period;  temperatures  below  32 ◦C  are
ess  neuroprotective,  and  very  severe  systemic  adverse
ffects  and  increased  mortality  have  been  observed  with
emperatures  below  30 ◦C.1,13,15 To  ensure  the  effective-
ess  and  safety  of  total  body  cooling,  the  esophageal  or
ectal  temperature  should  be  maintained  at  33.5 ◦C,  and
or  selective  head  cooling,  at  34.5 ◦C;  the  temperature
ust  be  continuously  monitored  in  both  situations.13 A
ecent  multicenter  study  demonstrated  no  beneﬁt  and  sug-
ested  deleterious  effects  with  a  total  body  cooling  protocol
ver  a  longer  period  of  time  (120  h)  or  lower  esophageal
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emperature  (32 ◦C)  or  both;  the  study  was  interrupted
efore  the  estimated  sample  size  was  achieved.32
All  protocols  of  studies  on  neuroprotection  after  HIE  with
herapeutic  hypothermia  had  similar  inclusion  criteria  (ges-
ational  age  >  35--36  weeks,  signiﬁcant  acidosis  or  severe
epression  at  birth,  moderate  to  severe  encephalopathy
ith  or  without  aEEG).  In  the  majority,  the  exclusion  criteria
ere  age  older  than  6  h  of  life,  chromosomal  abnormalities,
nd  major  congenital  malformations  or  severe  intrauterine
rowth  restriction.3,20,21,24--26
Although  a  recent  study  consecutively  compared  83  cases
f  therapeutic  hypothermia,  including  34  newborns  sub-
itted  to  selective  head  cooling  and  49  to  total  body
ooling,  the  ﬁndings  of  brain  damage  based  upon  MRI  were
ore  severe  and  frequent  in  the  selective  head  cooling
roup,  suggesting  greater  neuroprotection  in  newborns  who
ere  submitted  to  the  total  body  cooling  technique33;  how-
ver,  other  studies  suggest  the  same  beneﬁt  with  both
echniques.1
In  the  absence  of  adequate  conditions,  ventilation,  and
emodynamic  support,  as  well  as  constant  temperature
onitoring  at  every  stage,  cooling,  and  rewarming,  thera-
eutic  hypothermia  for  neonatal  HIE  has  shown  unfavorable
esults  and  is  not  recommended,  as  it  increases  mortality
n  these  conditions.34 Procedural  safety  requires  months  of
ultidisciplinary  team  training,  with  emphasis  on  under-
tanding  the  multisystemic  involvement  related  to  perinatal
sphyxia,  associated  with  potential  systemic  complications
f  this  treatment  modality.35
The  possible  adverse  effects  of  hypothermia  therapy
hould  be  carefully  monitored,  such  as  hypotension  and
rolonged  QT  interval,  thrombocytopenia,  and  clotting  dis-
rders  in  general  (altered  prothrombin  time  --  PT  and
ctivated  partial  thromboplastin  time  --  aPTT),  skin  burns
nd  scleredema,  and  metabolic  and  electrolytic  disorders.35
It  is  important  to  recognize  that  some  events  are  not
irectly  related  to  therapeutic  hypothermia  but  rather
o  multiorgan  dysfunction,  which  characterizes  hypoxic
schemic  syndrome  and  overlaps  with  the  adverse  effects
f  neonatal  therapeutic  hypothermia.  One  example  is  per-
istent  pulmonary  hypertension  (PPH),  directly  associated
ith  perinatal  asphyxia  and,  conversely,  hyperthermia  can
ause  hemoconcentration,  hyperviscosity,  and  pulmonary
asoconstriction.10,35 A  meta-analysis  of  four  randomized
linical  trials  showed  no  hypoglycemia  in  the  group  submit-
ed  to  therapeutic  hypothermia.1
These  adverse  events  are  more  associated  with  lower
emperatures  than  those  recommended  in  the  protocols,
hus  the  importance  of  careful  monitoring.  Adequate  knowl-
dge  of  how  hypothermia  affects  all  organ  systems  of
sphyxiated  newborns  that  are  already  severely  ill  is  crit-
cal  to  prevent  and  avoid  the  complications  of  exaggerated
ooling.35
The  pharmacokinetics  of  some  drugs  is  altered  by  cooling.
n  an  observational  study,  newborns  with  HIE  treated  with
ypothermia  and  receiving  normal  morphine  infusions  had
igniﬁcantly  higher  serum  concentrations  of  the  latter  when
ompared  to  the  group  with  normal  temperature.  There-
ore,  the  rate  of  morphine  infusion  must  be  lower  than  that
sually  recommended  during  therapeutic  hypothermia.36
All  the  evidence  suggests  that  the  neuroprotective
esponse  is  time-dependent  (therapeutic  window)  and  thatSilveira  RC,  Procianoy  RS
ffectiveness  depends  on  initiating  the  protocol  in  up  to  6  h.
n  practice,  it  is  necessary  to  consider  at  this  time,  that  the
rib  should  be  already  off  and  the  thermometer  should  be
nserted  (if  it  is  transesophageal,  a  chest  X-ray  is  obtained
o  assess  whether  it  is  well  placed;  i.e., middle-third  of
he  esophagus).  By  continually  assessing  body  temperature,
ven  before  using  the  total  body  hypothermia  mattress,  the
hysicians  ensure  the  safety  and  care  quality  of  the  protocol.
fter  72  h,  the  rewarming  phase  should  be  carefully  moni-
ored,  as  ﬂuctuations  in  cerebral  blood  ﬂow  are  associated
ith  brain  hemorrhage  after  fast  rewarming.  Near-infrared
pectroscopy  (NIRS)  is  an  effective  tool  to  monitor  brain
erfusion  changes  in  newborns  with  HIE  submitted  to  ther-
peutic  hypothermia.37
onclusion
herapeutic  hypothermia  signiﬁcantly  reduces  morbidity
nd  mortality  for  many  asphyxiated  newborns.  However,
ome  still  die  or  survive  with  sequelae  at  varying  levels  in
utpatient  follow-up,  demonstrating  the  need  for  associa-
ion  with  other  neuroprotective  strategies.  The  safety  and
ffectiveness  of  protocols  performed  in  reference  centers
ust  be  continuously  assessed.  In  this  review,  evidence  is
rovided  that  supports  the  beneﬁt  of  therapeutic  hypother-
ia  in  infants  with  moderate  encephalopathy.  A  future  goal
ill  be  ﬁnding  ways  to  improve  therapy  effectiveness.
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